Page 2 - Thorac Onc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Thorac onc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Thorac Onc Today - Breaking & Trending Today

TAGRISSO Extended Disease-Free Survival Regardless of Prior Adjuvant Chemotherapy in Early-Stage EGFR-Mutated Lung Cancer

In the ADAURA Phase III trial, chemotherapy use was balanced across the two treatment arms, with 60% of patients receiving prior adjuvant chemotherapy. In line with uptake observed in prior studies and clinical practice, younger patients ( ....

United States , Le Chevalier , Provence Alpes Côd Azur , United Kingdom , Long Wu , Dave Fredrickson , Daiichi Sankyo , Thorac Onc , Collaborative Group , Arch Pathol Lab , Single Institution Study , Us Community Oncology Practices , Academy Of Medical Sciences , World Health Organization , Lungevity Foundation , International Agency For Research On Cancer , Lung Cancer , International Association , Tenured Professor , Lung Cancer Institute , Guangdong Provincial People , Medical Sciences , Executive Vice President , Oncology Business Unit , New England Journal , Prescribing Information ,

Tagrisso approved in the US for the adjuvant treatment of patients...

AstraZeneca’s
Tagrisso (osimertinib) has been approved in the US for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after tumour resection with curative intent.
Tagrisso is indicated for EGFRm patients whose tumours have exon 19 deletions or exon 21 L858R mutations as detected by an approved test.
The approval was granted under the US Food and Drug Administration’s (FDA) Real-Time Oncology Review (RTOR) pilot program. Five other countries participated in a concurrent submission and review process through FDA’s Project Orbis.
While up to 30% of all patients with NSCLC may be diagnosed early enough to have potentially curative surgery, disease recurrence is still common in early-stage disease and nearly half of patients diagnosed in Stage IB, and over three quarters of patients diagnosed in Stage IIIA, experience recurrence within five years. ....

United States , United Kingdom , Dave Fredrickson , Thorac Onc , Astrazeneca Tagrisso , Roys Herbst , Le Chevalier , Company On Twitter , American Society Of Clinical Oncology , Oncology Center , Singapore Health Sciences Authority , Oncology At Yale Cancer Center , International Agency For Research On Cancer , Collaborative Group , Single Institution Study , Drug Administration , World Health Organization , Archives Pathology Lab , Data Monitoring Committee , Regulatory Agency , Australian Therapeutic Goods Administration , Lungevity Foundation , Brazilian Health Regulatory Agency Anvisa , Investor Relations Team , Health Canada , Real Time Oncology Review ,